Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
classical swine fever virus E2 subunit vaccine
- Development stage
- Unknown
- Lead developer
- Shenlian Biotech
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Classical Swine Fever Virus E2 subunit vaccine is a recombinant protein vaccine developed by Shen Lian Biotech for the prevention of Classical Swine Fever (CSF) in swine. The vaccine utilizes the E2 glycoprotein of the Classical Swine Fever Virus (CSFV), which is the primary target for neutralizing antibodies, expressed in a yeast system (Pichia pastoris). Unlike traditional live-attenuated C-strain vaccines, this subunit formulation is non-infectious and provides a DIVA (Differentiation of Infected from Vaccinated Animals) capability, allowing for better disease surveillance and eradication efforts. It is administered via intramuscular injection to stimulate a protective immune response against CSFV infection.
- Brand names
- Shen Lian
- Other names
- 猪瘟病毒E2亚单位疫苗猪瘟疫苗Classical Swine Fever Virus E2 subunit vaccine (yeast expression)
02
Targets
BVDV E2 (Bovine viral diarrhea virus glycoprotein E2)
Beyond the preview
Go deeper on classical swine fever virus E2 subunit vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on classical swine fever virus E2 subunit vaccine.